T 2048/19 (Glycopyrrolate for treating tachycardia /TEVA) of 20.07.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T204819.20230720
- Date of decision
- 20 July 2023
- Case number
- T 2048/19
- Petition for review of
- -
- Application number
- 12709151.0
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Use of glycopyrrolate for treating tachycardia
- Applicant name
- Heptares Therapeutics Limited
- Opponent name
- Teva Pharmaceuticals International GmbH
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(a)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Main request - novelty (no)
Auxiliary request 1 - late-filed - could have been filed in first instance proceedings (yes)
Auxiliary request 2 - novelty (no)
Auxiliary request 3 - late-filed - admitted (yes)
Auxiliary request 3 - sufficiency of disclosure, novelty, inventive step (yes) - Catchword
- -
- Cited cases
- T 0134/11
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent on the basis of the set of claims of auxiliary request 3 filed during the oral proceedings before the board and a description to be adapted thereto as necessary.